268 related articles for article (PubMed ID: 36952376)
1. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.
West J; Adler F; Gallaher J; Strobl M; Brady-Nicholls R; Brown J; Roberson-Tessi M; Kim E; Noble R; Viossat Y; Basanta D; Anderson ARA
Elife; 2023 Mar; 12():. PubMed ID: 36952376
[TBL] [Abstract][Full Text] [Related]
2. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
Brady-Nicholls R; Zhang J; Zhang T; Wang AZ; Butler R; Gatenby RA; Enderling H
Neoplasia; 2021 Sep; 23(9):851-858. PubMed ID: 34298234
[TBL] [Abstract][Full Text] [Related]
3. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes.
Zhang J; Cunningham J; Brown J; Gatenby R
Elife; 2022 Jun; 11():. PubMed ID: 35762577
[TBL] [Abstract][Full Text] [Related]
4. The 2019 mathematical oncology roadmap.
Rockne RC; Hawkins-Daarud A; Swanson KR; Sluka JP; Glazier JA; Macklin P; Hormuth DA; Jarrett AM; Lima EABF; Tinsley Oden J; Biros G; Yankeelov TE; Curtius K; Al Bakir I; Wodarz D; Komarova N; Aparicio L; Bordyuh M; Rabadan R; Finley SD; Enderling H; Caudell J; Moros EG; Anderson ARA; Gatenby RA; Kaznatcheev A; Jeavons P; Krishnan N; Pelesko J; Wadhwa RR; Yoon N; Nichol D; Marusyk A; Hinczewski M; Scott JG
Phys Biol; 2019 Jun; 16(4):041005. PubMed ID: 30991381
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models.
Kim E; Brown JS; Eroglu Z; Anderson ARA
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669315
[TBL] [Abstract][Full Text] [Related]
6. Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
Ibrahim-Hashim A; Robertson-Tessi M; Enriquez-Navas PM; Damaghi M; Balagurunathan Y; Wojtkowiak JW; Russell S; Yoonseok K; Lloyd MC; Bui MM; Brown JS; Anderson ARA; Gillies RJ; Gatenby RA
Cancer Res; 2017 May; 77(9):2242-2254. PubMed ID: 28249898
[TBL] [Abstract][Full Text] [Related]
7. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.
Gallaher J; Strobl M; West J; Gatenby R; Zhang J; Robertson-Tessi M; Anderson ARA
Cancer Res; 2023 Aug; 83(16):2775-2789. PubMed ID: 37205789
[TBL] [Abstract][Full Text] [Related]
8. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
Zhang J; Cunningham JJ; Brown JS; Gatenby RA
Nat Commun; 2017 Nov; 8(1):1816. PubMed ID: 29180633
[TBL] [Abstract][Full Text] [Related]
9. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Hamid AA; Sayegh N; Tombal B; Hussain M; Sweeney CJ; Graff JN; Agarwal N
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390166. PubMed ID: 37220335
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling in melanoma for novel drug discovery.
Pennisi M; Russo G; Di Salvatore V; Candido S; Libra M; Pappalardo F
Expert Opin Drug Discov; 2016 Jun; 11(6):609-21. PubMed ID: 27046143
[TBL] [Abstract][Full Text] [Related]
12. Towards Multidrug Adaptive Therapy.
West J; You L; Zhang J; Gatenby RA; Brown JS; Newton PK; Anderson ARA
Cancer Res; 2020 Apr; 80(7):1578-1589. PubMed ID: 31948939
[TBL] [Abstract][Full Text] [Related]
13. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.
West J; Ma Y; Newton PK
J Theor Biol; 2018 Oct; 455():249-260. PubMed ID: 30048718
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer.
Mason NT; Burkett JM; Nelson RS; Pow-Sang JM; Gatenby RA; Kubal T; Peabody JW; Letson GD; McLeod HL; Zhang J
Am Health Drug Benefits; 2021 Mar; 14(1):15-20. PubMed ID: 33841621
[TBL] [Abstract][Full Text] [Related]
15. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
Cunningham JJ; Brown JS; Gatenby RA; Staňková K
J Theor Biol; 2018 Dec; 459():67-78. PubMed ID: 30243754
[TBL] [Abstract][Full Text] [Related]
16. Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.
Gallagher K; Strobl MA; Park DS; Spoendlin FC; Gatenby RA; Maini PK; Anderson AR
Cancer Res; 2024 Apr; ():. PubMed ID: 38569183
[TBL] [Abstract][Full Text] [Related]
17. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.
Gallaher J; Cook LM; Gupta S; Araujo A; Dhillon J; Park JY; Scott JG; Pow-Sang J; Basanta D; Lynch CC
Clin Exp Metastasis; 2014 Dec; 31(8):991-9. PubMed ID: 25173680
[TBL] [Abstract][Full Text] [Related]
18. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.
Smalley I; Kim E; Li J; Spence P; Wyatt CJ; Eroglu Z; Sondak VK; Messina JL; Babacan NA; Maria-Engler SS; De Armas L; Williams SL; Gatenby RA; Chen YA; Anderson ARA; Smalley KSM
EBioMedicine; 2019 Oct; 48():178-190. PubMed ID: 31594749
[TBL] [Abstract][Full Text] [Related]
19. Fighting Cancer with Mathematics and Viruses.
Santiago DN; Heidbuechel JPW; Kandell WM; Walker R; Djeu J; Engeland CE; Abate-Daga D; Enderling H
Viruses; 2017 Aug; 9(9):. PubMed ID: 28832539
[TBL] [Abstract][Full Text] [Related]
20. Predictability and identifiability assessment of models for prostate cancer under androgen suppression therapy.
Wu Z; Phan T; Baez J; Kuang Y; Kostelich EJ
Math Biosci Eng; 2019 Apr; 16(5):3512-3536. PubMed ID: 31499626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
